SiteBridge Research and iParticipate Launch Annual Bridging the Gap in Clinical Trials Arts Contest
SiteBridge Research, together with iParticipate, is kicking off its annual Bridging the Gap in Clinical Trials Arts contest. This effort officially launches SiteBridge's community engagement program and aims to connect the arts, sciences, and community in support of clinical trial participation.
The contest began on June 14 with voting commencing on August 7. Winners will be notified on November 20. It will feature talent across four categories: visual art, music, photography, and dance.
SiteBridge's creative collaboration with iParticipate, incorporated in the "Bridging the Gap" initiative compels industry to examine how it addresses disparities and how it portrays clinical trials—especially to communities of color and other underrepresented populations—and will explore the potential for impact.
Read more about the initiative and contest here.
Reference
Bridging the Gap Community Engagement Program. (2023, June 14). SiteBridge Research.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
